Equidad en salud en las pruebas de biomarcadores y terapias dirigidas
La terapia dirigida puede mejorar la supervivencia y la calidad de vida al conectar a los pacientes con el tratamiento más beneficioso para su enfermedad.
Understanding Provider Utilization of Cancer Biomarker Testing
December 7, 2021
Biomarker testing is an important step to accessing precision medicine, including targeted therapies that can lead to improved survivorship and better quality of life for cancer patients. However, not all communities are benefitting from the latest advancements in biomarker testing and precision medicine. ACS CAN is working to dismantle barriers that prevent patients from benefiting from biomarker testing and precision medicine, and working to ensure all patients benefit, regardless of race, ethnicity, gender, age, sexual orientation, socioeconomic status, or zip code.
ACS CAN conducted a survey of 315 oncology providers examining barriers providers face in performing recommended cancer biomarker testing. The survey found that providers face challenges such as lab turnaround time, patient concerns about out-of-pocket-costs, and insurance coverage of biomarker tests.